FL_genes.md
... ...
@@ -1,821 +1,145 @@
1
+---
2
+title: 'FL genes'
3
+bibliography: 'morinlab.bib'
4
+csl: 'NLM.csl'
5
+link-citations: true
6
+---
7
+
1 8
# FL genes
2 9
3 10
## Origins of FL genes
4
-```mermaid
5
----
6
-config:
7
- sankey:
8
- showValues: false
9
- linkColor: target
10
- width: 800
11
- height: 1000
12
- nodeAlignment: right
13
----
14
-sankey-beta
15
-Okosun 2016, FL Tier 1, 2
16
-Russler-germain 2023, FL Tier 1, 1
17
-Russler-germain 2023, FL Tier 2, 19
18
-Krysiak 2017, FL Tier 1, 17
19
-Krysiak 2017, FL Tier 2, 5
20
-Morin 2011, FL Tier 1, 14
21
-Morin 2011, FL Tier 2, 1
22
-Pasqualucci 2011, FL Tier 1, 2
23
-Hubschmann 2021, FL Tier 1, 2
24
-Hubschmann 2021, FL Tier 2, 15
25
-FL, WGS, 2
26
-WGS, Okosun 2016, 2
27
-FL, exome, 20
28
-exome, Russler-germain 2023, 20
29
-FL, exome, 2
30
-exome, Pasqualucci 2011, 2
31
-FL, WGS, 17
32
-WGS, Hubschmann 2021, 17
33
-FL, exome, 22
34
-exome, Krysiak 2017, 22
35
-FL, RNA-seq/WGS, 15
36
-RNA-seq/WGS, Morin 2011, 15
37
-```
11
+
12
+![](FL_sankey-1.svg)
38 13
39 14
## Tier 1 FL genes
40 15
41 16
### *66 total*
42 17
43
-| Gene | Tier | Relevant references |
44
-|:----------------------:|:-------:|:--------------------------------------------------------------------------------------------------------|
45
-| [ACTB](ACTB) | 1, aSHM | Lohr et al. 2012; Wienand et al. 2019 |
46
-| [ARID1A](ARID1A) | 1 | Zhang et al. 2013; Wienand et al. 2019; Love et al. 2012; Krysiak et al. 2017; Rossi et al. 2012 |
47
-| [ATP6AP1](ATP6AP1) | 1 | Okosun et al. 2016 |
48
-| [ATP6V1B2](ATP6V1B2) | 1 | Okosun et al. 2016 |
49
-| [B2M](B2M) | 1 | Morin et al. 2011; Pararajalingam et al. 2020; Reichel et al. 2015 |
50
-| [BCL2](BCL2) | 1, aSHM | Sarkozy et al. 2021; Tanaka et al. 1992; Burkhardt et al. 2022; Morin et al. 2011 |
51
-| [BCL6](BCL6) | 1, aSHM | Morin et al. 2011; Love et al. 2012 |
52
-| [BCL7A](BCL7A) | 1, aSHM | Reichel et al. 2015; Grande et al. 2019; Krysiak et al. 2017; Arthur et al. 2018 |
53
-| [BIRC6](BIRC6) | 1 | Sarkozy et al. 2021; Reddy et al. 2017 |
54
-| [BTG1](BTG1) | 1, aSHM | Sarkozy et al. 2021; Burkhardt et al. 2022; Morin et al. 2011 |
55
-| [BTG2](BTG2) | 1, aSHM | Love et al. 2012; Morin et al. 2011 |
56
-| [BTK](BTK) | 1 | Krysiak et al. 2017; Albuquerque et al. 2017 |
57
-| [CARD11](CARD11) | 1 | Yan et al. 2012; Lenz et al. 2008; Morin et al. 2011; Panea et al. 2019; Wu et al. 2016 |
58
-| [CCND3](CCND3) | 1 | Desch et al. 2020; Jallades et al. 2017; Richter et al. 2012; Morin et al. 2011 |
59
-| [CD83](CD83) | 1, aSHM | Russler-Germain et al. 2023; Panea et al. 2019; Duns et al. 2021; Morin et al. 2013 |
60
-| [CREBBP](CREBBP) | 1 | Duns et al. 2021; Laura Pasqualucci, Dominguez-Sola, et al. 2011; Love et al. 2012; Parry et al. 2013 |
61
-| [CTSS](CTSS) | 1 | Bararia et al. 2020 |
62
-| [DTX1](DTX1) | 1, aSHM | Rossi et al. 2012; Panea et al. 2019; Gomez et al. 2023; Schmitz et al. 2018 |
63
-| [EBF1](EBF1) | 1, aSHM | Reichel et al. 2015; Thomas et al. 2023; Bohle et al. 2013 |
64
-| [EEF1A1](EEF1A1) | 1 | Reichel et al. 2015; Hübschmann et al. 2021 |
65
-| [EP300](EP300) | 1 | Laura Pasqualucci, Dominguez-Sola, et al. 2011; Panea et al. 2019; Rossi et al. 2012 |
66
-| [EZH2](EZH2) | 1 | Morin et al. 2010; Love et al. 2012; Mottok et al. 2019 |
67
-| [FAS](FAS) | 1 | Scholl et al. 2007; Spina et al. 2016 |
68
-| [FOXO1](FOXO1) | 1 | Morin et al. 2011; Schmitz et al. 2012; Duns et al. 2021 |
69
-| [GNA13](GNA13) | 1 | Love et al. 2012; Morin et al. 2011; Reichel et al. 2015 |
70
-| [GNAI2](GNAI2) | 1 | Morin et al. 2013; Grande et al. 2019 |
71
-| [HIST1H1B](HIST1H1B) | 1, aSHM | Sarkozy et al. 2021; Chapuy et al. 2018; Krysiak et al. 2017 |
72
-| [HIST1H1C](HIST1H1C) | 1, aSHM | Morin et al. 2011; Panea et al. 2019 |
73
-| [HIST1H1D](HIST1H1D) | 1, aSHM | Krysiak et al. 2017; Morin et al. 2013; Jallades et al. 2017 |
74
-| [HIST1H1E](HIST1H1E) | 1, aSHM | Reichel et al. 2015; Morin et al. 2013; Krysiak et al. 2017; Grande et al. 2019 |
75
-| [HIST1H2AC](HIST1H2AC) | 1, aSHM | Krysiak et al. 2017; Morin et al. 2013 |
76
-| [HIST1H2AG](HIST1H2AG) | 1, aSHM | Krysiak et al. 2017; Panea et al. 2019; Morin et al. 2013; Rossi et al. 2012 |
77
-| [HIST1H2AM](HIST1H2AM) | 1, aSHM | Panea et al. 2019; Krysiak et al. 2017 |
78
-| [HIST1H2BC](HIST1H2BC) | 1, aSHM | Mottok et al. 2019; Krysiak et al. 2017; Reddy et al. 2017 |
79
-| [HIST1H2BD](HIST1H2BD) | 1, aSHM | Krysiak et al. 2017 |
80
-| [HIST1H2BG](HIST1H2BG) | 1, aSHM | Krysiak et al. 2017 |
81
-| [HIST1H3B](HIST1H3B) | 1, aSHM | Zhang et al. 2013; Reichel et al. 2015 |
82
-| [HIST1H3G](HIST1H3G) | 1, aSHM | Krysiak et al. 2017 |
83
-| [HVCN1](HVCN1) | 1 | Krysiak et al. 2017 |
84
-| [IRF4](IRF4) | 1, aSHM | Mottok et al. 2019; Morin et al. 2011 |
85
-| [IRF8](IRF8) | 1, aSHM | Panea et al. 2019; Morin et al. 2011; Mottok et al. 2019 |
86
-| [ITPKB](ITPKB) | 1, aSHM | Schmitz et al. 2018; Reichel et al. 2015 |
87
-| [KLF2](KLF2) | 1, aSHM | Laura Pasqualucci, Trifonov, et al. 2011; Desch et al. 2020; Jallades et al. 2017 |
88
-| [KLHL6](KLHL6) | 1, aSHM | Panea et al. 2019; Ganapathi et al. 2016; Morin et al. 2011 |
89
-| [KMT2D](KMT2D) | 1 | Rossi et al. 2012; Desch et al. 2020; Morin et al. 2011; Beà et al. 2013; Grande et al. 2019 |
90
-| [LTB](LTB) | 1, aSHM | Desch et al. 2020; Chapuy et al. 2018; Panea et al. 2019 |
91
-| [MAP2K1](MAP2K1) | 1 | Shin et al. 2015; Louissaint et al. 2016 |
92
-| [MEF2B](MEF2B) | 1, aSHM | Beà et al. 2013; Morin et al. 2011 |
93
-| [MEF2C](MEF2C) | 1, aSHM | Arthur et al. 2018 |
94
-| [PCLO](PCLO) | 1 | Lohr et al. 2012 |
95
-| [PIM1](PIM1) | 1, aSHM | Duns et al. 2021; L. Pasqualucci et al. 2001; Burkhardt et al. 2022 |
96
-| [POU2AF1](POU2AF1) | 1 | Krysiak et al. 2017 |
97
-| [POU2F2](POU2F2) | 1 | Zhang et al. 2013; Krysiak et al. 2017 |
98
-| [PTPRD](PTPRD) | 1 | Spina et al. 2016 |
99
-| [RRAGC](RRAGC) | 1 | Okosun et al. 2016 |
100
-| [S1PR2](S1PR2) | 1, aSHM | Morin et al. 2011; Muppidi et al. 2014 |
101
-| [SGK1](SGK1) | 1, aSHM | Morin et al. 2011; Duns et al. 2021 |
102
-| [SMARCA4](SMARCA4) | 1 | Zhang et al. 2013; Nadeu et al. 2020; Krysiak et al. 2017; Richter et al. 2012 |
103
-| [SOCS1](SOCS1) | 1, aSHM | Morin et al. 2011; Weniger et al. 2006 |
104
-| [STAT6](STAT6) | 1 | Yildiz et al. 2015; Ritz et al. 2009 |
105
-| [TBL1XR1](TBL1XR1) | 1 | Rossi et al. 2012; Mareschal et al. 2016 |
106
-| [TMSB4X](TMSB4X) | 1, aSHM | Albuquerque et al. 2017 |
107
-| [TNFAIP3](TNFAIP3) | 1 | Schmitz et al. 2009; Compagno et al. 2009; Rossi et al. 2011 |
108
-| [TNFRSF14](TNFRSF14) | 1 | Cheung et al. 2010; Spina et al. 2016 |
109
-| [TP53](TP53) | 1 | Wilda et al. 2004; Rossi et al. 2012; Beà et al. 2013; Tiacci et al. 2018; Morin et al. 2011 |
110
-| [VMA21](VMA21) | 1 | Hübschmann et al. 2021 |
18
+|Gene|Tier| Relevant references|
19
+|:-:|:-:|:-|
20
+|[ACTB](ACTB)|1, aSHM|[@wienandGenomicAnalysesFlowsorted2019b; @lohrDiscoveryPrioritizationSomatic2012a]|
21
+|[ARID1A](ARID1A)|1|[@zhangGeneticHeterogeneityDiffuse2013; @krysiakRecurrentSomaticMutations2017b; @wienandGenomicAnalysesFlowsorted2019b; @rossiCodingGenomeSplenic2012c; @loveGeneticLandscapeMutations2012]|
22
+|[ATP6AP1](ATP6AP1)|1|[@okosunRecurrentMTORC1activatingRRAGC2016a]|
23
+|[ATP6V1B2](ATP6V1B2)|1|[@okosunRecurrentMTORC1activatingRRAGC2016a]|
24
+|[B2M](B2M)|1|[@reichelFlowSortingExome2015a; @morinFrequentMutationHistonemodifying2011; @pararajalingamCodingNoncodingDrivers2020]|
25
+|[BCL2](BCL2)|1, aSHM|[@tanakaFrequentIncidenceSomatic1992; @burkhardtClinicalRelevanceMolecular2022b; @sarkozyMutationalLandscapeGray2021a; @morinFrequentMutationHistonemodifying2011]|
26
+|[BCL6](BCL6)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @loveGeneticLandscapeMutations2012]|
27
+|[BCL7A](BCL7A)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b; @arthurGenomewideDiscoverySomatic2018; @reichelFlowSortingExome2015a; @grandeGenomewideDiscoverySomatic2019]|
28
+|[BIRC6](BIRC6)|1|[@sarkozyMutationalLandscapeGray2021a; @reddyGeneticFunctionalDrivers2017]|
29
+|[BTG1](BTG1)|1, aSHM|[@sarkozyMutationalLandscapeGray2021a; @burkhardtClinicalRelevanceMolecular2022b; @morinFrequentMutationHistonemodifying2011]|
30
+|[BTG2](BTG2)|1, aSHM|[@loveGeneticLandscapeMutations2012; @morinFrequentMutationHistonemodifying2011]|
31
+|[BTK](BTK)|1|[@krysiakRecurrentSomaticMutations2017b; @albuquerqueEnhancingKnowledgeDiscovery2017a]|
32
+|[CARD11](CARD11)|1|[@yanBCRTLRSignaling2012a; @wuGeneticHeterogeneityPrimary2016; @paneaWholeGenomeLandscape2019; @lenzOncogenicCARD11Mutations2008; @morinFrequentMutationHistonemodifying2011]|
33
+|[CCND3](CCND3)|1|[@deschGenotypingCirculatingTumor2020; @jalladesExomeSequencingIdentifies2017; @richterRecurrentMutationID32012a; @morinFrequentMutationHistonemodifying2011]|
34
+|[CD83](CD83)|1, aSHM|[@morinMutationalStructuralAnalysis2013; @russler-germainMutationsAssociatedProgression2023b; @dunsCharacterizationDLBCLPMBL2021b; @paneaWholeGenomeLandscape2019]|
35
+|[CREBBP](CREBBP)|1|[@parryWholeExomeSequencing2013; @pasqualucciInactivatingMutationsAcetyltransferase2011a; @dunsCharacterizationDLBCLPMBL2021b; @loveGeneticLandscapeMutations2012]|
36
+|[CTSS](CTSS)|1|[@barariaCathepsinAlterationsInduce2020c]|
37
+|[DTX1](DTX1)|1, aSHM|[@rossiCodingGenomeSplenic2012c; @paneaWholeGenomeLandscape2019; @gomezUltraDeepSequencingReveals2023; @schmitzGeneticsPathogenesisDiffuse2018a]|
38
+|[EBF1](EBF1)|1, aSHM|[@reichelFlowSortingExome2015a; @thomasGeneticSubgroupsInform2023; @bohleRoleEarlyBcell2013]|
39
+|[EEF1A1](EEF1A1)|1|[@hubschmannMutationalMechanismsShaping2021b; @reichelFlowSortingExome2015a]|
40
+|[EP300](EP300)|1|[@rossiCodingGenomeSplenic2012c; @pasqualucciInactivatingMutationsAcetyltransferase2011a; @paneaWholeGenomeLandscape2019]|
41
+|[EZH2](EZH2)|1|[@loveGeneticLandscapeMutations2012; @morinSomaticMutationsAltering2010a; @mottokIntegrativeGenomicAnalysis2019b]|
42
+|[FAS](FAS)|1|[@spinaGeneticsNodalMarginal2016b; @schollMutationsRegionFAS2007]|
43
+|[FOXO1](FOXO1)|1|[@morinFrequentMutationHistonemodifying2011; @dunsCharacterizationDLBCLPMBL2021b; @schmitzBurkittLymphomaPathogenesis2012]|
44
+|[GNA13](GNA13)|1|[@loveGeneticLandscapeMutations2012; @morinFrequentMutationHistonemodifying2011; @reichelFlowSortingExome2015a]|
45
+|[GNAI2](GNAI2)|1|[@morinMutationalStructuralAnalysis2013; @grandeGenomewideDiscoverySomatic2019]|
46
+|[HIST1H1B](HIST1H1B)|1, aSHM|[@chapuyMolecularSubtypesDiffuse2018b; @krysiakRecurrentSomaticMutations2017b; @sarkozyMutationalLandscapeGray2021a]|
47
+|[HIST1H1C](HIST1H1C)|1, aSHM|[@paneaWholeGenomeLandscape2019; @morinFrequentMutationHistonemodifying2011]|
48
+|[HIST1H1D](HIST1H1D)|1, aSHM|[@morinMutationalStructuralAnalysis2013; @jalladesExomeSequencingIdentifies2017; @krysiakRecurrentSomaticMutations2017b]|
49
+|[HIST1H1E](HIST1H1E)|1, aSHM|[@reichelFlowSortingExome2015a; @krysiakRecurrentSomaticMutations2017b; @grandeGenomewideDiscoverySomatic2019; @morinMutationalStructuralAnalysis2013]|
50
+|[HIST1H2AC](HIST1H2AC)|1, aSHM|[@morinMutationalStructuralAnalysis2013; @krysiakRecurrentSomaticMutations2017b]|
51
+|[HIST1H2AG](HIST1H2AG)|1, aSHM|[@rossiCodingGenomeSplenic2012c; @morinMutationalStructuralAnalysis2013; @krysiakRecurrentSomaticMutations2017b; @paneaWholeGenomeLandscape2019]|
52
+|[HIST1H2AM](HIST1H2AM)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b; @paneaWholeGenomeLandscape2019]|
53
+|[HIST1H2BC](HIST1H2BC)|1, aSHM|[@reddyGeneticFunctionalDrivers2017; @krysiakRecurrentSomaticMutations2017b; @mottokIntegrativeGenomicAnalysis2019b]|
54
+|[HIST1H2BD](HIST1H2BD)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b]|
55
+|[HIST1H2BG](HIST1H2BG)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b]|
56
+|[HIST1H3B](HIST1H3B)|1, aSHM|[@reichelFlowSortingExome2015a; @zhangGeneticHeterogeneityDiffuse2013]|
57
+|[HIST1H3G](HIST1H3G)|1, aSHM|[@krysiakRecurrentSomaticMutations2017b]|
58
+|[HVCN1](HVCN1)|1|[@krysiakRecurrentSomaticMutations2017b]|
59
+|[IRF4](IRF4)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @mottokIntegrativeGenomicAnalysis2019b]|
60
+|[IRF8](IRF8)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @mottokIntegrativeGenomicAnalysis2019b; @paneaWholeGenomeLandscape2019]|
61
+|[ITPKB](ITPKB)|1, aSHM|[@schmitzGeneticsPathogenesisDiffuse2018a; @reichelFlowSortingExome2015a]|
62
+|[KLF2](KLF2)|1, aSHM|[@deschGenotypingCirculatingTumor2020; @jalladesExomeSequencingIdentifies2017; @pasqualucciAnalysisCodingGenome2011]|
63
+|[KLHL6](KLHL6)|1, aSHM|[@paneaWholeGenomeLandscape2019; @ganapathiGeneticLandscapeDural2016; @morinFrequentMutationHistonemodifying2011]|
64
+|[KMT2D](KMT2D)|1|[@morinFrequentMutationHistonemodifying2011; @deschGenotypingCirculatingTumor2020; @grandeGenomewideDiscoverySomatic2019; @beaLandscapeSomaticMutations2013; @rossiCodingGenomeSplenic2012c]|
65
+|[LTB](LTB)|1, aSHM|[@chapuyMolecularSubtypesDiffuse2018b; @deschGenotypingCirculatingTumor2020; @paneaWholeGenomeLandscape2019]|
66
+|[MAP2K1](MAP2K1)|1|[@louissaintPediatrictypeNodalFollicular2016a; @shinBRAFV600EMAP2K12015]|
67
+|[MEF2B](MEF2B)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @beaLandscapeSomaticMutations2013]|
68
+|[MEF2C](MEF2C)|1, aSHM|[@arthurGenomewideDiscoverySomatic2018]|
69
+|[PCLO](PCLO)|1|[@lohrDiscoveryPrioritizationSomatic2012a]|
70
+|[PIM1](PIM1)|1, aSHM|[@pasqualucciHypermutationMultipleProtooncogenes2001a; @dunsCharacterizationDLBCLPMBL2021b; @burkhardtClinicalRelevanceMolecular2022b]|
71
+|[POU2AF1](POU2AF1)|1|[@krysiakRecurrentSomaticMutations2017b]|
72
+|[POU2F2](POU2F2)|1|[@zhangGeneticHeterogeneityDiffuse2013; @krysiakRecurrentSomaticMutations2017b]|
73
+|[PTPRD](PTPRD)|1|[@spinaGeneticsNodalMarginal2016b]|
74
+|[RRAGC](RRAGC)|1|[@okosunRecurrentMTORC1activatingRRAGC2016a]|
75
+|[S1PR2](S1PR2)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @muppidiLossSignalingGa132014b]|
76
+|[SGK1](SGK1)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @dunsCharacterizationDLBCLPMBL2021b]|
77
+|[SMARCA4](SMARCA4)|1|[@zhangGeneticHeterogeneityDiffuse2013; @krysiakRecurrentSomaticMutations2017b; @nadeuGenomicEpigenomicInsights2020b; @richterRecurrentMutationID32012a]|
78
+|[SOCS1](SOCS1)|1, aSHM|[@morinFrequentMutationHistonemodifying2011; @wenigerMutationsTumorSuppressor2006a]|
79
+|[STAT6](STAT6)|1|[@yildizActivatingSTAT6Mutations2015c; @ritzRecurrentMutationsSTAT62009a]|
80
+|[TBL1XR1](TBL1XR1)|1|[@mareschalWholeExomeSequencing2016; @rossiCodingGenomeSplenic2012c]|
81
+|[TMSB4X](TMSB4X)|1, aSHM|[@albuquerqueEnhancingKnowledgeDiscovery2017a]|
82
+|[TNFAIP3](TNFAIP3)|1|[@rossiAlterationBIRC3Multiple2011a; @schmitzTNFAIP3A20Tumor2009a; @compagnoMutationsMultipleGenes2009a]|
83
+|[TNFRSF14](TNFRSF14)|1|[@spinaGeneticsNodalMarginal2016b; @cheungAcquiredTNFRSF14Mutations2010a]|
84
+|[TP53](TP53)|1|[@rossiCodingGenomeSplenic2012c; @beaLandscapeSomaticMutations2013; @tiacciPervasiveMutationsJAKSTAT2018b; @morinFrequentMutationHistonemodifying2011; @wildaInactivationARFMDM2p53Pathway2004]|
85
+|[VMA21](VMA21)|1|[@hubschmannMutationalMechanismsShaping2021b]|
111 86
112 87
## Tier 2 FL genes
113 88
114 89
### *50 total*
115 90
116
-| Gene | Tier | Relevant references |
117
-|:----------------------:|:-------:|:------------------------------------------------------------------------------------------------|
118
-| [ABL2](ABL2) | 2 | Russler-Germain et al. 2023 |
119
-| [ACTG1](ACTG1) | 2, aSHM | Hübschmann et al. 2021; Spina et al. 2016; Desch et al. 2020 |
120
-| [ATP6V1A](ATP6V1A) | 2 | Hübschmann et al. 2021 |
121
-| [BCL10](BCL10) | 2 | Spina et al. 2016; Russler-Germain et al. 2023; Morin et al. 2011 |
122
-| [CCDC42BPB](CCDC42BPB) | 2 | Hübschmann et al. 2021 |
123
-| [CD70](CD70) | 2 | Morin et al. 2011; Russler-Germain et al. 2023 |
124
-| [CD79B](CD79B) | 2 | Morin et al. 2011; Panea et al. 2019 |
125
-| [CILP](CILP) | 2 | Russler-Germain et al. 2023 |
126
-| [CPNE8](CPNE8) | 2 | Hübschmann et al. 2021 |
127
-| [CXCR4](CXCR4) | 2, aSHM | Krysiak et al. 2017; Panea et al. 2019; Khodabakhshi et al. 2012 |
128
-| [CYP2A6](CYP2A6) | 2 | Russler-Germain et al. 2023 |
129
-| [DDX3X](DDX3X) | 2 | Schmitz et al. 2018, 2012; Mottok et al. 2019 |
130
-| [DHX15](DHX15) | 2 | Hübschmann et al. 2021 |
131
-| [DUSP2](DUSP2) | 2, aSHM | Morin et al. 2013; Duns et al. 2021 |
132
-| [EGR1](EGR1) | 2 | Krysiak et al. 2017; Rossi et al. 2012; Reichel et al. 2015 |
133
-| [FZR1](FZR1) | 2 | Hübschmann et al. 2021 |
134
-| [GBP7](GBP7) | 2 | Russler-Germain et al. 2023 |
135
-| [GRM6](GRM6) | 2 | Russler-Germain et al. 2023 |
136
-| [HIST1H2BM](HIST1H2BM) | 2, aSHM | Krysiak et al. 2017 |
137
-| [HIST1H3I](HIST1H3I) | 2, aSHM | Panea et al. 2019; Krysiak et al. 2017 |
138
-| [HLA-B](HLA-B) | 2 | Wienand et al. 2019 |
139
-| [HNRNPD](HNRNPD) | 2 | |
140
-| [IGLL5](IGLL5) | 2, aSHM | Russler-Germain et al. 2023; Desch et al. 2020; Panea et al. 2019 |
141
-| [JUP](JUP) | 2 | Hübschmann et al. 2021 |
142
-| [KIR3DL1](KIR3DL1) | 2 | Russler-Germain et al. 2023 |
143
-| [LAPTM5](LAPTM5) | 2 | Hübschmann et al. 2021 |
144
-| [MAGEC1](MAGEC1) | 2 | Russler-Germain et al. 2023 |
145
-| [MAP7D1](MAP7D1) | 2 | Russler-Germain et al. 2023 |
146
-| [MGEA5](MGEA5) | 2 | Hübschmann et al. 2021 |
147
-| [MKI67](MKI67) | 2 | Russler-Germain et al. 2023; Schmitz et al. 2012 |
148
-| [MYC](MYC) | 2, aSHM | Johnston and Carroll 1992; L. Pasqualucci et al. 2001; Jallades et al. 2017; Duns et al. 2021 |
149
-| [MYCBP2](MYCBP2) | 2 | Hübschmann et al. 2021 |
150
-| [MYD88](MYD88) | 2 | Ngo et al. 2011; Yan et al. 2012 |
151
-| [NFKBIA](NFKBIA) | 2 | Wienand et al. 2019; Russler-Germain et al. 2023; Lake et al. 2009 |
152
-| [OR8H2](OR8H2) | 2 | Russler-Germain et al. 2023 |
153
-| [P2RY8](P2RY8) | 2 | Muppidi et al. 2014; Lohr et al. 2012 |
154
-| [PDS5B](PDS5B) | 2 | Morin et al. 2013; Hübschmann et al. 2021 |
155
-| [PPP4C](PPP4C) | 2 | Hübschmann et al. 2021 |
156
-| [PRKDC](PRKDC) | 2 | Schmitz et al. 2018; Hübschmann et al. 2021 |
157
-| [PZP](PZP) | 2 | Russler-Germain et al. 2023 |
158
-| [RBM6](RBM6) | 2 | Hübschmann et al. 2021 |
159
-| [SESN1](SESN1) | 2 | Oricchio et al. 2017 |
160
-| [SHROOM3](SHROOM3) | 2 | Russler-Germain et al. 2023 |
161
-| [SRRM2](SRRM2) | 2 | Morin et al. 2013; Russler-Germain et al. 2023 |
162
-| [STAB2](STAB2) | 2 | Russler-Germain et al. 2023 |
163
-| [TMEM30A](TMEM30A) | 2 | Morin et al. 2011 |
164
-| [TPP1](TPP1) | 2 | Hübschmann et al. 2021 |
165
-| [XIRP2](XIRP2) | 2 | Russler-Germain et al. 2023 |
166
-| [ZC3H12A](ZC3H12A) | 2 | Arthur et al. 2018 |
167
-| [ZNF608](ZNF608) | 2 | Zhang et al. 2013; Krysiak et al. 2017 |
168
-
169
-# References
170
-
171
-<div id="refs" class="references csl-bib-body hanging-indent">
172
-
173
-<div id="ref-albuquerqueEnhancingKnowledgeDiscovery2017a"
174
-class="csl-entry">
175
-
176
-Albuquerque, Marco A., Bruno M. Grande, Elie J. Ritch, Prasath
177
-Pararajalingam, Selin Jessa, Martin Krzywinski, Jasleen K. Grewal,
178
-Sohrab P. Shah, Paul C. Boutros, and Ryan D. Morin. 2017. “Enhancing
179
-Knowledge Discovery from Cancer Genomics Data with Galaxy.”
180
-*GigaScience* 6 5: 1–13. <https://doi.org/10.1093/gigascience/gix015>.
181
-
182
-</div>
183
-
184
-<div id="ref-arthurGenomewideDiscoverySomatic2018" class="csl-entry">
185
-
186
-Arthur, Sarah E., Aixiang Jiang, Bruno M. Grande, Miguel Alcaide, Razvan
187
-Cojocaru, Christopher K. Rushton, Anja Mottok, et al. 2018. “Genome-Wide
188
-Discovery of Somatic Regulatory Variants in Diffuse Large <span
189
-class="nocase">B-cell</span> Lymphoma.” *Nature Communications* 9 1:
190
-4001. <https://doi.org/10.1038/s41467-018-06354-3>.
191
-
192
-</div>
193
-
194
-<div id="ref-barariaCathepsinAlterationsInduce2020c" class="csl-entry">
195
-
196
-Bararia, Deepak, Johannes A. Hildebrand, Sebastian Stolz, Sarah Haebe,
197
-Stefan Alig, Christopher P. Trevisani, Francisco Osorio-Barrios, et al.
198
-2020. “Cathepsin S Alterations Induce a Tumor-Promoting Immune
199
-Microenvironment in Follicular Lymphoma.” *Cell Reports* 31 5: 107522.
200
-<https://doi.org/10.1016/j.celrep.2020.107522>.
201
-
202
-</div>
203
-
204
-<div id="ref-beaLandscapeSomaticMutations2013" class="csl-entry">
205
-
206
-Beà, Sílvia, Rafael Valdés-Mas, Alba Navarro, Itziar Salaverria, David
207
-Martín-Garcia, Pedro Jares, Eva Giné, et al. 2013. “Landscape of Somatic
208
-Mutations and Clonal Evolution in Mantle Cell Lymphoma.” *Proceedings of
209
-the National Academy of Sciences* 110 45: 18250–55.
210
-<https://doi.org/10.1073/pnas.1314608110>.
211
-
212
-</div>
213
-
214
-<div id="ref-bohleRoleEarlyBcell2013" class="csl-entry">
215
-
216
-Bohle, V., C. Döring, M.-L. Hansmann, and R. Küppers. 2013. “Role of
217
-Early <span class="nocase">B-cell</span> Factor 1 EBF1 in Hodgkin
218
-Lymphoma.” *Leukemia* 27 3: 671–79.
219
-<https://doi.org/10.1038/leu.2012.280>.
220
-
221
-</div>
222
-
223
-<div id="ref-burkhardtClinicalRelevanceMolecular2022b"
224
-class="csl-entry">
225
-
226
-Burkhardt, Birgit, Ulf Michgehl, Jonas Rohde, Tabea Erdmann, Philipp
227
-Berning, Katrin Reutter, Marius Rohde, et al. 2022. “Clinical Relevance
228
-of Molecular Characteristics in Burkitt Lymphoma Differs According to
229
-Age.” *Nature Communications* 13 1: 3881.
230
-<https://doi.org/10.1038/s41467-022-31355-8>.
231
-
232
-</div>
233
-
234
-<div id="ref-chapuyMolecularSubtypesDiffuse2018b" class="csl-entry">
235
-
236
-Chapuy, Bjoern, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Atanas
237
-Kamburov, Robert A. Redd, Mike S. Lawrence, et al. 2018. “Molecular
238
-Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct
239
-Pathogenic Mechanisms and Outcomes.” *Nature Medicine* 24 5: 679–90.
240
-<https://doi.org/10.1038/s41591-018-0016-8>.
241
-
242
-</div>
243
-
244
-<div id="ref-cheungAcquiredTNFRSF14Mutations2010a" class="csl-entry">
245
-
246
-Cheung, K.-John J., Nathalie A. Johnson, Joslynn G. Affleck, Tesa
247
-Severson, Christian Steidl, Susana Ben-Neriah, Jacqueline Schein, et al.
248
-2010. “Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated
249
-with Worse Prognosis.” *Cancer Research* 70 22: 9166–74.
250
-<https://doi.org/10.1158/0008-5472.CAN-10-2460>.
251
-
252
-</div>
253
-
254
-<div id="ref-compagnoMutationsMultipleGenes2009a" class="csl-entry">
255
-
256
-Compagno, Mara, Wei Keat Lim, Adina Grunn, Subhadra V. Nandula, Manisha
257
-Brahmachary, Qiong Shen, Francesco Bertoni, et al. 2009. “Mutations of
258
-Multiple Genes Cause Deregulation of <span
259
-class="nocase">NF-kappaB</span> in Diffuse Large <span
260
-class="nocase">B-cell</span> Lymphoma.” *Nature* 459 7247: 717–21.
261
-<https://doi.org/10.1038/nature07968>.
262
-
263
-</div>
264
-
265
-<div id="ref-deschGenotypingCirculatingTumor2020" class="csl-entry">
266
-
267
-Desch, Ann-Kathrin, Kristin Hartung, Ante Botzen, Alexander Brobeil,
268
-Mathias Rummel, Lars Kurch, Thomas Georgi, et al. 2020. “Genotyping
269
-Circulating Tumor DNA of Pediatric Hodgkin Lymphoma.” *Leukemia* 34 1:
270
-151–66. <https://doi.org/10.1038/s41375-019-0541-6>.
271
-
272
-</div>
273
-
274
-<div id="ref-dunsCharacterizationDLBCLPMBL2021b" class="csl-entry">
275
-
276
-Duns, Gerben, Elena Viganò, Daisuke Ennishi, Clementine Sarkozy, Stacy
277
-S. Hung, Elizabeth Chavez, Katsuyoshi Takata, et al. 2021.
278
-“Characterization of DLBCL with a PMBL Gene Expression Signature.”
279
-*Blood* 138 2: 136–48. <https://doi.org/10.1182/blood.2020007683>.
280
-
281
-</div>
282
-
283
-<div id="ref-ganapathiGeneticLandscapeDural2016" class="csl-entry">
284
-
285
-Ganapathi, Karthik A., Vaidehi Jobanputra, Fabio Iwamoto, Preti Jain,
286
-Jinli Chen, Luciano Cascione, Odelia Nahum, et al. 2016. “The Genetic
287
-Landscape of Dural Marginal Zone Lymphomas.” *Oncotarget* 7 28:
288
-43052–61. <https://doi.org/10.18632/oncotarget.9678>.
289
-
290
-</div>
291
-
292
-<div id="ref-gomezUltraDeepSequencingReveals2023" class="csl-entry">
293
-
294
-Gomez, Felicia, Bryan Fisk, Joshua F. McMichael, Matthew Mosior,
295
-Jennifer A. Foltz, Zachary L. Skidmore, Eric J. Duncavage, et al. 2023.
296
-“Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical
297
-Hodgkin Lymphoma.” *Cancer Research Communications* 3 11: 2312–30.
298
-<https://doi.org/10.1158/2767-9764.CRC-23-0140>.
299
-
300
-</div>
301
-
302
-<div id="ref-grandeGenomewideDiscoverySomatic2019" class="csl-entry">
303
-
304
-Grande, Bruno M., Daniela S. Gerhard, Aixiang Jiang, Nicholas B. Griner,
305
-Jeremy S. Abramson, Thomas B. Alexander, Hilary Allen, et al. 2019.
306
-“Genome-Wide Discovery of Somatic Coding and Noncoding Mutations in
307
-Pediatric Endemic and Sporadic Burkitt Lymphoma.” *Blood* 133 12:
308
-1313–24. <https://doi.org/10.1182/blood-2018-09-871418>.
309
-
310
-</div>
311
-
312
-<div id="ref-hubschmannMutationalMechanismsShaping2021b"
313
-class="csl-entry">
314
-
315
-Hübschmann, Daniel, Kortine Kleinheinz, Rabea Wagener, Stephan H.
316
-Bernhart, Cristina López, Umut H. Toprak, Stephanie Sungalee, et al.
317
-2021. “Mutational Mechanisms Shaping the Coding and Noncoding Genome of
318
-Germinal Center Derived <span class="nocase">B-cell</span> Lymphomas.”
319
-*Leukemia* 35 7: 2002–16.
320
-<https://doi.org/10.1038/s41375-021-01251-z>.
321
-
322
-</div>
323
-
324
-<div id="ref-jalladesExomeSequencingIdentifies2017" class="csl-entry">
325
-
326
-Jallades, Laurent, Lucile Baseggio, Pierre Sujobert, Sarah Huet, Kaddour
327
-Chabane, Evelyne Callet-Bauchu, Aurélie Verney, et al. 2017. “Exome
328
-Sequencing Identifies Recurrent BCOR Alterations and the Absence of
329
-KLF2, TNFAIP3 and MYD88 Mutations in Splenic Diffuse Red Pulp Small
330
-<span class="nocase">B-cell</span> Lymphoma.” *Haematologica* 102 10:
331
-1758–66. <https://doi.org/10.3324/haematol.2016.160192>.
332
-
333
-</div>
334
-
335
-<div id="ref-johnstonCmycHypermutationBurkitt1992" class="csl-entry">
336
-
337
-Johnston, J. M., and W. L. Carroll. 1992. “C-Myc Hypermutation in
338
-Burkitt’s Lymphoma.” *Leukemia & Lymphoma* 8 6: 431–39.
339
-<https://doi.org/10.3109/10428199209051025>.
340
-
341
-</div>
342
-
343
-<div id="ref-khodabakhshiRecurrentTargetsAberrant2012"
344
-class="csl-entry">
345
-
346
-Khodabakhshi, Alireza Hadj, Ryan D. Morin, Anthony P. Fejes, Andrew J.
347
-Mungall, Karen L. Mungall, Madison Bolger-Munro, Nathalie A. Johnson, et
348
-al. 2012. “Recurrent Targets of Aberrant Somatic Hypermutation in
349
-Lymphoma.” *Oncotarget* 3 11: 1308–19.
350
-<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717795/>.
351
-
352
-</div>
353
-
354
-<div id="ref-krysiakRecurrentSomaticMutations2017b" class="csl-entry">
355
-
356
-Krysiak, Kilannin, Felicia Gomez, Brian S. White, Matthew Matlock,
357
-Christopher A. Miller, Lee Trani, Catrina C. Fronick, et al. 2017.
358
-“Recurrent Somatic Mutations Affecting <span
359
-class="nocase">B-cell</span> Receptor Signaling Pathway Genes in
360
-Follicular Lymphoma.” *Blood* 129 4: 473–83.
361
-<https://doi.org/10.1182/blood-2016-07-729954>.
362
-
363
-</div>
364
-
365
-<div id="ref-lakeMutationsNFKBIAEncoding2009" class="csl-entry">
366
-
367
-Lake, Annette, Lesley A. Shield, Pablo Cordano, Daniel T. Y. Chui, Julie
368
-Osborne, Shauna Crae, Katherine S. Wilson, et al. 2009. “Mutations of
369
-NFKBIA, Encoding IkappaB Alpha, Are a Recurrent Finding in Classical
370
-Hodgkin Lymphoma but Are Not a Unifying Feature of Non-<span
371
-class="nocase">EBV-associated</span> Cases.” *International Journal of
372
-Cancer* 125 6: 1334–42. <https://doi.org/10.1002/ijc.24502>.
373
-
374
-</div>
375
-
376
-<div id="ref-lenzOncogenicCARD11Mutations2008" class="csl-entry">
377
-
378
-Lenz, Georg, R Eric Davis, Vu N Ngo, Lloyd Lam, Thaddeus C George,
379
-George W Wright, Sandeep S Dave, et al. 2008. “Oncogenic CARD11
380
-Mutations in Human Diffuse Large B Cell Lymphoma.” *Science* 319 5870:
381
-1676–79.
382
-
383
-</div>
384
-
385
-<div id="ref-lohrDiscoveryPrioritizationSomatic2012a" class="csl-entry">
386
-
387
-Lohr, Jens G., Petar Stojanov, Michael S. Lawrence, Daniel Auclair,
388
-Bjoern Chapuy, Carrie Sougnez, Peter Cruz-Gordillo, et al. 2012.
389
-“Discovery and Prioritization of Somatic Mutations in Diffuse Large
390
-<span class="nocase">B-cell</span> Lymphoma DLBCL by Whole-Exome
391
-Sequencing.” *Proceedings of the National Academy of Sciences of the
392
-United States of America* 109 10: 3879–84.
393
-<https://doi.org/10.1073/pnas.1121343109>.
394
-
395
-</div>
396
-
397
-<div id="ref-louissaintPediatrictypeNodalFollicular2016a"
398
-class="csl-entry">
399
-
400
-Louissaint, Abner, Kristian T. Schafernak, Julia T. Geyer, Alexandra E.
401
-Kovach, Mahmoud Ghandi, Dita Gratzinger, Christine G. Roth, et al. 2016.
402
-“Pediatric-Type Nodal Follicular Lymphoma: A Biologically Distinct
403
-Lymphoma with Frequent MAPK Pathway Mutations.” *Blood* 128 8:
404
-1093–1100. <https://doi.org/10.1182/blood-2015-12-682591>.
405
-
406
-</div>
407
-
408
-<div id="ref-loveGeneticLandscapeMutations2012" class="csl-entry">
409
-
410
-Love, Cassandra, Zhen Sun, Dereje Jima, Guojie Li, Jenny Zhang, Rodney
411
-Miles, Kristy L. Richards, et al. 2012. “The Genetic Landscape of
412
-Mutations in Burkitt Lymphoma.” *Nature Genetics* 44 12: 1321–25.
413
-<https://doi.org/10.1038/ng.2468>.
414
-
415
-</div>
416
-
417
-<div id="ref-mareschalWholeExomeSequencing2016" class="csl-entry">
418
-
419
-Mareschal, Sylvain, Sydney Dubois, Pierre-Julien Viailly, Philippe
420
-Bertrand, Elodie Bohers, Catherine Maingonnat, Jean-Philippe Jaïs, et
421
-al. 2016. “Whole Exome Sequencing of Relapsed/Refractory Patients
422
-Expands the Repertoire of Somatic Mutations in Diffuse Large <span
423
-class="nocase">B-cell</span> Lymphoma.” *Genes, Chromosomes & Cancer* 55
424
-3: 251–67. <https://doi.org/10.1002/gcc.22328>.
425
-
426
-</div>
427
-
428
-<div id="ref-morinSomaticMutationsAltering2010a" class="csl-entry">
429
-
430
-Morin, Ryan D., Nathalie A. Johnson, Tesa M. Severson, Andrew J.
431
-Mungall, Jianghong An, Rodrigo Goya, Jessica E. Paul, et al. 2010.
432
-“Somatic Mutations Altering EZH2 Tyr641 in Follicular and Diffuse
433
-Large <span class="nocase">B-cell</span> Lymphomas of Germinal-Center
434
-Origin.” *Nature Genetics* 42 2: 181–85.
435
-<https://doi.org/10.1038/ng.518>.
436
-
437
-</div>
438
-
439
-<div id="ref-morinFrequentMutationHistonemodifying2011"
440
-class="csl-entry">
441
-
442
-Morin, Ryan D., Maria Mendez-Lago, Andrew J. Mungall, Rodrigo Goya,
443
-Karen L. Mungall, Richard D. Corbett, Nathalie A. Johnson, et al. 2011.
444
-“Frequent Mutation of Histone-Modifying Genes in Non-Hodgkin Lymphoma.”
445
-*Nature* 476 7360: 298–303. <https://doi.org/10.1038/nature10351>.
446
-
447
-</div>
448
-
449
-<div id="ref-morinMutationalStructuralAnalysis2013" class="csl-entry">
450
-
451
-Morin, Ryan D., Karen Mungall, Erin Pleasance, Andrew J. Mungall,
452
-Rodrigo Goya, Ryan D. Huff, David W. Scott, et al. 2013. “Mutational and
453
-Structural Analysis of Diffuse Large <span class="nocase">B-cell</span>
454
-Lymphoma Using Whole-Genome Sequencing.” *Blood* 122 7: 1256–65.
455
-<https://doi.org/10.1182/blood-2013-02-483727>.
456
-
457
-</div>
458
-
459
-<div id="ref-mottokIntegrativeGenomicAnalysis2019b" class="csl-entry">
460
-
461
-Mottok, Anja, Stacy S. Hung, Elizabeth A. Chavez, Bruce Woolcock, Adèle
462
-Telenius, Lauren C. Chong, Barbara Meissner, et al. 2019. “Integrative
463
-Genomic Analysis Identifies Key Pathogenic Mechanisms in Primary
464
-Mediastinal Large <span class="nocase">B-cell</span> Lymphoma.” *Blood*
465
-134 10: 802–13. <https://doi.org/10.1182/blood.2019001126>.
466
-
467
-</div>
468
-
469
-<div id="ref-muppidiLossSignalingGa132014b" class="csl-entry">
470
-
471
-Muppidi, J., R. Schmitz, Jesse A. Green, Jesse A. Green, Wenming Xiao,
472
-Adrien B. Larsen, S. Braun, et al. 2014. “Loss of Signaling via Gα13 in
473
-Germinal Center B Cell-Derived Lymphoma.” *Nature* 516: 254–58.
474
-<https://doi.org/10.1038/nature13765>.
475
-
476
-</div>
477
-
478
-<div id="ref-nadeuGenomicEpigenomicInsights2020b" class="csl-entry">
479
-
480
-Nadeu, F., D. Martín-García, G. Clot, A. Díaz-Navarro, M. Duran-Ferrer,
481
-A. Navarro, Roser Vilarrasa-Blasi, et al. 2020. “Genomic and Epigenomic
482
-Insights into the Origin, Pathogenesis and Clinical Behavior of Mantle
483
-Cell Lymphoma Subtypes.” *Blood*.
484
-<https://doi.org/10.1182/blood.2020005289>.
91
+|Gene|Tier| Relevant references|
92
+|:-:|:-:|:-|
93
+|[ABL2](ABL2)|2|[@russler-germainMutationsAssociatedProgression2023b]|
94
+|[ACTG1](ACTG1)|2, aSHM|[@spinaGeneticsNodalMarginal2016b; @hubschmannMutationalMechanismsShaping2021b; @deschGenotypingCirculatingTumor2020]|
95
+|[ATP6V1A](ATP6V1A)|2|[@hubschmannMutationalMechanismsShaping2021b]|
96
+|[BCL10](BCL10)|2|[@spinaGeneticsNodalMarginal2016b; @russler-germainMutationsAssociatedProgression2023b; @morinFrequentMutationHistonemodifying2011]|
97
+|[CCDC42BPB](CCDC42BPB)|2|[@hubschmannMutationalMechanismsShaping2021b]|
98
+|[CD70](CD70)|2|[@morinFrequentMutationHistonemodifying2011; @russler-germainMutationsAssociatedProgression2023b]|
99
+|[CD79B](CD79B)|2|[@morinFrequentMutationHistonemodifying2011; @paneaWholeGenomeLandscape2019]|
100
+|[CILP](CILP)|2|[@russler-germainMutationsAssociatedProgression2023b]|
101
+|[CPNE8](CPNE8)|2|[@hubschmannMutationalMechanismsShaping2021b]|
102
+|[CXCR4](CXCR4)|2, aSHM|[@paneaWholeGenomeLandscape2019; @khodabakhshiRecurrentTargetsAberrant2012; @krysiakRecurrentSomaticMutations2017b]|
103
+|[CYP2A6](CYP2A6)|2|[@russler-germainMutationsAssociatedProgression2023b]|
104
+|[DDX3X](DDX3X)|2|[@schmitzBurkittLymphomaPathogenesis2012; @mottokIntegrativeGenomicAnalysis2019b; @schmitzGeneticsPathogenesisDiffuse2018a]|
105
+|[DHX15](DHX15)|2|[@hubschmannMutationalMechanismsShaping2021b]|
106
+|[DUSP2](DUSP2)|2, aSHM|[@dunsCharacterizationDLBCLPMBL2021b; @morinMutationalStructuralAnalysis2013]|
107
+|[EGR1](EGR1)|2|[@krysiakRecurrentSomaticMutations2017b; @reichelFlowSortingExome2015a; @rossiCodingGenomeSplenic2012c]|
108
+|[FZR1](FZR1)|2|[@hubschmannMutationalMechanismsShaping2021b]|
109
+|[GBP7](GBP7)|2|[@russler-germainMutationsAssociatedProgression2023b]|
110
+|[GRM6](GRM6)|2|[@russler-germainMutationsAssociatedProgression2023b]|
111
+|[HIST1H2BM](HIST1H2BM)|2, aSHM|[@krysiakRecurrentSomaticMutations2017b]|
112
+|[HIST1H3I](HIST1H3I)|2, aSHM|[@paneaWholeGenomeLandscape2019; @krysiakRecurrentSomaticMutations2017b]|
113
+|[HLA-B](HLA-B)|2|[@wienandGenomicAnalysesFlowsorted2019b]|
114
+|[HNRNPD](HNRNPD)|2||
115
+|[IGLL5](IGLL5)|2, aSHM|[@paneaWholeGenomeLandscape2019; @russler-germainMutationsAssociatedProgression2023b; @deschGenotypingCirculatingTumor2020]|
116
+|[JUP](JUP)|2|[@hubschmannMutationalMechanismsShaping2021b]|
117
+|[KIR3DL1](KIR3DL1)|2|[@russler-germainMutationsAssociatedProgression2023b]|
118
+|[LAPTM5](LAPTM5)|2|[@hubschmannMutationalMechanismsShaping2021b]|
119
+|[MAGEC1](MAGEC1)|2|[@russler-germainMutationsAssociatedProgression2023b]|
120
+|[MAP7D1](MAP7D1)|2|[@russler-germainMutationsAssociatedProgression2023b]|
121
+|[MGEA5](MGEA5)|2|[@hubschmannMutationalMechanismsShaping2021b]|
122
+|[MKI67](MKI67)|2|[@schmitzBurkittLymphomaPathogenesis2012; @russler-germainMutationsAssociatedProgression2023b]|
123
+|[MYC](MYC)|2, aSHM|[@jalladesExomeSequencingIdentifies2017; @pasqualucciHypermutationMultipleProtooncogenes2001a; @johnstonCmycHypermutationBurkitt1992; @dunsCharacterizationDLBCLPMBL2021b]|
124
+|[MYCBP2](MYCBP2)|2|[@hubschmannMutationalMechanismsShaping2021b]|
125
+|[MYD88](MYD88)|2|[@yanBCRTLRSignaling2012a; @ngoOncogenicallyActiveMYD882011a]|
126
+|[NFKBIA](NFKBIA)|2|[@lakeMutationsNFKBIAEncoding2009; @russler-germainMutationsAssociatedProgression2023b; @wienandGenomicAnalysesFlowsorted2019b]|
127
+|[OR8H2](OR8H2)|2|[@russler-germainMutationsAssociatedProgression2023b]|
128
+|[P2RY8](P2RY8)|2|[@lohrDiscoveryPrioritizationSomatic2012a; @muppidiLossSignalingGa132014b]|
129
+|[PDS5B](PDS5B)|2|[@morinMutationalStructuralAnalysis2013; @hubschmannMutationalMechanismsShaping2021b]|
130
+|[PPP4C](PPP4C)|2|[@hubschmannMutationalMechanismsShaping2021b]|
131
+|[PRKDC](PRKDC)|2|[@schmitzGeneticsPathogenesisDiffuse2018a; @hubschmannMutationalMechanismsShaping2021b]|
132
+|[PZP](PZP)|2|[@russler-germainMutationsAssociatedProgression2023b]|
133
+|[RBM6](RBM6)|2|[@hubschmannMutationalMechanismsShaping2021b]|
134
+|[SESN1](SESN1)|2|[@oricchioGeneticEpigeneticInactivation2017b]|
135
+|[SHROOM3](SHROOM3)|2|[@russler-germainMutationsAssociatedProgression2023b]|
136
+|[SRRM2](SRRM2)|2|[@russler-germainMutationsAssociatedProgression2023b; @morinMutationalStructuralAnalysis2013]|
137
+|[STAB2](STAB2)|2|[@russler-germainMutationsAssociatedProgression2023b]|
138
+|[TMEM30A](TMEM30A)|2|[@morinFrequentMutationHistonemodifying2011]|
139
+|[TPP1](TPP1)|2|[@hubschmannMutationalMechanismsShaping2021b]|
140
+|[XIRP2](XIRP2)|2|[@russler-germainMutationsAssociatedProgression2023b]|
141
+|[ZC3H12A](ZC3H12A)|2|[@arthurGenomewideDiscoverySomatic2018]|
142
+|[ZNF608](ZNF608)|2|[@zhangGeneticHeterogeneityDiffuse2013; @krysiakRecurrentSomaticMutations2017b]|
485 143
486
-</div>
487 144
488
-<div id="ref-ngoOncogenicallyActiveMYD882011a" class="csl-entry">
489
-
490
-Ngo, Vu N., Ryan M. Young, Roland Schmitz, Sameer Jhavar, Wenming Xiao,
491
-Kian-Huat Lim, Holger Kohlhammer, et al. 2011. “Oncogenically Active
492
-MYD88 Mutations in Human Lymphoma.” *Nature* 470 7332: 115–19.
493
-<https://doi.org/10.1038/nature09671>.
494
-
495
-</div>
496
-
497
-<div id="ref-okosunRecurrentMTORC1activatingRRAGC2016a"
498
-class="csl-entry">
499
-
500
-Okosun, Jessica, Rachel L. Wolfson, Jun Wang, Shamzah Araf, Lucy
501
-Wilkins, Brian M. Castellano, Leire Escudero-Ibarz, et al. 2016.
502
-“Recurrent <span class="nocase">mTORC1-activating RRAGC</span> Mutations
503
-in Follicular Lymphoma.” *Nature Genetics* 48 2: 183–88.
504
-<https://doi.org/10.1038/ng.3473>.
505
-
506
-</div>
507
-
508
-<div id="ref-oricchioGeneticEpigeneticInactivation2017b"
509
-class="csl-entry">
510
-
511
-Oricchio, Elisa, Natalya Katanayeva, Maria Christine Donaldson,
512
-Stephanie Sungalee, Joyce P. Pasion, Wendy Béguelin, Elena Battistello,
513
-et al. 2017. “Genetic and Epigenetic Inactivation of SESTRIN1 Controls
514
-<span class="nocase">mTORC1</span> and Response to EZH2 Inhibition in
515
-Follicular Lymphoma.” *Science Translational Medicine* 9 396:
516
-eaak9969. <https://doi.org/10.1126/scitranslmed.aak9969>.
517
-
518
-</div>
519
-
520
-<div id="ref-paneaWholeGenomeLandscape2019" class="csl-entry">
521
-
522
-Panea, R., C. Love, Jennifer R. Shingleton, Anupama Reddy, J. Bailey, A.
523
-Moormann, J. Otieno, et al. 2019. “The Whole Genome Landscape of Burkitt
524
-Lymphoma Subtypes.” *Blood*. <https://doi.org/10.1182/blood.2019001880>.
525
-
526
-</div>
527
-
528
-<div id="ref-pararajalingamCodingNoncodingDrivers2020"
529
-class="csl-entry">
530
-
531
-Pararajalingam, Prasath, Krysta M. Coyle, Sarah E. Arthur, Nicole
532
-Thomas, Miguel Alcaide, Barbara Meissner, Merrill Boyle, et al. 2020.
533
-“Coding and Noncoding Drivers of Mantle Cell Lymphoma Identified Through
534
-Exome and Genome Sequencing.” *Blood* 136 5: 572–84.
535
-<https://doi.org/10.1182/blood.2019002385>.
536
-
537
-</div>
538
-
539
-<div id="ref-parryWholeExomeSequencing2013" class="csl-entry">
540
-
541
-Parry, Marina, Matthew J. J. Rose-Zerilli, Jane Gibson, Sarah Ennis,
542
-Renata Walewska, Jade Forster, Helen Parker, et al. 2013. “Whole Exome
543
-Sequencing Identifies Novel Recurrently Mutated Genes in Patients with
544
-Splenic Marginal Zone Lymphoma.” *PloS One* 8 12: e83244.
545
-<https://doi.org/10.1371/journal.pone.0083244>.
546
-
547
-</div>
548
-
549
-<div id="ref-pasqualucciInactivatingMutationsAcetyltransferase2011a"
550
-class="csl-entry">
551
-
552
-Pasqualucci, Laura, David Dominguez-Sola, Annalisa Chiarenza, Giulia
553
-Fabbri, Adina Grunn, Vladimir Trifonov, Lawryn H. Kasper, et al. 2011.
554
-“Inactivating Mutations of Acetyltransferase Genes in <span
555
-class="nocase">B-cell</span> Lymphoma.” *Nature* 471 7337: 189–95.
556
-<https://doi.org/10.1038/nature09730>.
557
-
558
-</div>
559
-
560
-<div id="ref-pasqualucciAnalysisCodingGenome2011" class="csl-entry">
561
-
562
-Pasqualucci, Laura, Vladimir Trifonov, Giulia Fabbri, Jing Ma, Davide
563
-Rossi, Annalisa Chiarenza, Victoria A. Wells, et al. 2011. “Analysis of
564
-the Coding Genome of Diffuse Large <span class="nocase">B-cell</span>
565
-Lymphoma.” *Nature Genetics* 43 9: 830–37.
566
-<https://doi.org/10.1038/ng.892>.
567
-
568
-</div>
569
-
570
-<div id="ref-pasqualucciHypermutationMultipleProtooncogenes2001a"
571
-class="csl-entry">
572
-
573
-Pasqualucci, L., P. Neumeister, T. Goossens, G. Nanjangud, R. S.
574
-Chaganti, R. Küppers, and R. Dalla-Favera. 2001. “Hypermutation of
575
-Multiple Proto-Oncogenes in <span class="nocase">B-cell</span> Diffuse
576
-Large-Cell Lymphomas.” *Nature* 412 6844: 341–46.
577
-<https://doi.org/10.1038/35085588>.
578
-
579
-</div>
580
-
581
-<div id="ref-reddyGeneticFunctionalDrivers2017" class="csl-entry">
582
-
583
-Reddy, Anupama, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt,
584
-Cassandra L Love, Alexander Waldrop, Sirpa Leppa, et al. 2017. “Genetic
585
-and Functional Drivers of Diffuse Large B Cell Lymphoma.” *Cell* 171
586
-2: 481–494.e15.
587
-
588
-</div>
589
-
590
-<div id="ref-reichelFlowSortingExome2015a" class="csl-entry">
591
-
592
-Reichel, Jonathan, Amy Chadburn, Paul G. Rubinstein, Lisa Giulino-Roth,
593
-Wayne Tam, Yifang Liu, Rafael Gaiolla, et al. 2015. “Flow Sorting and
594
-Exome Sequencing Reveal the Oncogenome of Primary Hodgkin and
595
-Reed-Sternberg Cells.” *Blood* 125 7: 1061–72.
596
-<https://doi.org/10.1182/blood-2014-11-610436>.
597
-
598
-</div>
599
-
600
-<div id="ref-richterRecurrentMutationID32012a" class="csl-entry">
601
-
602
-Richter, Julia, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen
603
-Leich, Birgit Burkhardt, Maciej Rosolowski, et al. 2012. “Recurrent
604
-Mutation of the ID3 Gene in Burkitt Lymphoma Identified by Integrated
605
-Genome, Exome and Transcriptome Sequencing.” *Nature Genetics* 44 12:
606
-1316–20. <https://doi.org/10.1038/ng.2469>.
607
-
608
-</div>
609
-
610
-<div id="ref-ritzRecurrentMutationsSTAT62009a" class="csl-entry">
611
-
612
-Ritz, Olga, Chrystelle Guiter, Flavia Castellano, Karola Dorsch, Julia
613
-Melzner, Jean-Philippe Jais, Gwendoline Dubois, Philippe Gaulard, Peter
614
-Möller, and Karen Leroy. 2009. “Recurrent Mutations of the STAT6 DNA
615
-Binding Domain in Primary Mediastinal <span class="nocase">B-cell</span>
616
-Lymphoma.” *Blood* 114 6: 1236–42.
617
-<https://doi.org/10.1182/blood-2009-03-209759>.
618
-
619
-</div>
620
-
621
-<div id="ref-rossiAlterationBIRC3Multiple2011a" class="csl-entry">
622
-
623
-Rossi, Davide, Silvia Deaglio, David Dominguez-Sola, Silvia Rasi,
624
-Tiziana Vaisitti, Claudio Agostinelli, Valeria Spina, et al. 2011.
625
-“Alteration of BIRC3 and Multiple Other <span
626
-class="nocase">NF-κB</span> Pathway Genes in Splenic Marginal Zone
627
-Lymphoma.” *Blood* 118 18: 4930–34.
628
-<https://doi.org/10.1182/blood-2011-06-359166>.
629
-
630
-</div>
631
-
632
-<div id="ref-rossiCodingGenomeSplenic2012c" class="csl-entry">
633
-
634
-Rossi, Davide, Vladimir Trifonov, Marco Fangazio, Alessio Bruscaggin,
635
-Silvia Rasi, Valeria Spina, Sara Monti, et al. 2012. “The Coding Genome
636
-of Splenic Marginal Zone Lymphoma: Activation of NOTCH2 and Other
637
-Pathways Regulating Marginal Zone Development.” *The Journal of
638
-Experimental Medicine* 209 9: 1537–51.
639
-<https://doi.org/10.1084/jem.20120904>.
640
-
641
-</div>
642
-
643
-<div id="ref-russler-germainMutationsAssociatedProgression2023b"
644
-class="csl-entry">
645
-
646
-Russler-Germain, David A., Kilannin Krysiak, Cody A. Ramirez, Matthew
647
-Mosior, Marcus P. Watkins, Felicia Gomez, Zachary L. Skidmore, et al.
648
-2023. “Mutations Associated with Progression in Follicular Lymphoma
649
-Predict Inferior Outcomes at Diagnosis: Alliance A151303.” *Blood
650
-Advances* 7: 5524–39.
651
-<https://doi.org/10.1182/bloodadvances.2023010779>.
652
-
653
-</div>
654
-
655
-<div id="ref-sarkozyMutationalLandscapeGray2021a" class="csl-entry">
656
-
657
-Sarkozy, Clémentine, Stacy S. Hung, Elizabeth A. Chavez, Gerben Duns,
658
-Katsuyoshi Takata, Lauren C. Chong, Tomohiro Aoki, et al. 2021.
659
-“Mutational Landscape of Gray Zone Lymphoma.” *Blood* 137 13: 1765–76.
660
-<https://doi.org/10.1182/blood.2020007507>.
661
-
662
-</div>
663
-
664
-<div id="ref-schmitzTNFAIP3A20Tumor2009a" class="csl-entry">
665
-
666
-Schmitz, Roland, Martin-Leo Hansmann, Verena Bohle, Jose Ignacio
667
-Martin-Subero, Sylvia Hartmann, Gunhild Mechtersheimer, Wolfram Klapper,
668
-et al. 2009. “TNFAIP3 A20 Is a Tumor Suppressor Gene in Hodgkin
669
-Lymphoma and Primary Mediastinal B Cell Lymphoma.” *The Journal of
670
-Experimental Medicine* 206 5: 981–89.
671
-<https://doi.org/10.1084/jem.20090528>.
672
-
673
-</div>
674
-
675
-<div id="ref-schmitzGeneticsPathogenesisDiffuse2018a" class="csl-entry">
676
-
677
-Schmitz, Roland, George W. Wright, Da Wei Huang, Calvin A. Johnson,
678
-James D. Phelan, James Q. Wang, Sandrine Roulland, et al. 2018.
679
-“Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.” *The New
680
-England Journal of Medicine* 378 15: 1396–1407.
681
-<https://doi.org/10.1056/NEJMoa1801445>.
682
-
683
-</div>
684
-
685
-<div id="ref-schmitzBurkittLymphomaPathogenesis2012" class="csl-entry">
686
-
687
-Schmitz, Roland, Ryan M. Young, Michele Ceribelli, Sameer Jhavar,
688
-Wenming Xiao, Meili Zhang, George Wright, et al. 2012. “Burkitt Lymphoma
689
-Pathogenesis and Therapeutic Targets from Structural and Functional
690
-Genomics.” *Nature* 490 7418: 116–20.
691
-<https://doi.org/10.1038/nature11378>.
692
-
693
-</div>
694
-
695
-<div id="ref-schollMutationsRegionFAS2007" class="csl-entry">
696
-
697
-Scholl, Vanesa, Claudio Gustavo Stefanoff, Rocio Hassan, Nelson Spector,
698
-and Ilana Zalcberg Renault. 2007. “Mutations Within the 5’ Region of
699
-FAS/CD95 Gene in Nodal Diffuse Large <span class="nocase">B-cell</span>
700
-Lymphoma.” *Leukemia & Lymphoma* 48 5: 957–63.
701
-<https://doi.org/10.1080/10428190701230858>.
702
-
703
-</div>
704
-
705
-<div id="ref-shinBRAFV600EMAP2K12015" class="csl-entry">
706
-
707
-Shin, Sang-Yong, Seung-Tae Lee, Hee-Jin Kim, Chang-Seok Ki, Chul Won
708
-Jung, Jong-Won Kim, and Sun-Hee Kim. 2015. “BRAF V600E and MAP2K1
709
-Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma
710
-Cases.” *Annals of Laboratory Medicine* 35 2: 257–59.
711
-<https://doi.org/10.3343/alm.2015.35.2.257>.
712
-
713
-</div>
714
-
715
-<div id="ref-spinaGeneticsNodalMarginal2016b" class="csl-entry">
716
-
717
-Spina, Valeria, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano
718
-Cascione, Alessio Bruscaggin, Elisa Spaccarotella, et al. 2016. “The
719
-Genetics of Nodal Marginal Zone Lymphoma.” *Blood* 128 10: 1362–73.
720
-<https://doi.org/10.1182/blood-2016-02-696757>.
721
-
722
-</div>
723
-
724
-<div id="ref-tanakaFrequentIncidenceSomatic1992" class="csl-entry">
725
-
726
-Tanaka, S., D. C. Louie, J. A. Kant, and J. C. Reed. 1992. “Frequent
727
-Incidence of Somatic Mutations in Translocated BCL2 Oncogenes of
728
-Non-Hodgkin’s Lymphomas.” *Blood* 79 1: 229–37.
729
-
730
-</div>
731
-
732
-<div id="ref-thomasGeneticSubgroupsInform2023" class="csl-entry">
733
-
734
-Thomas, Nicole, Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton,
735
-Jeremy S. Abramson, Richard F. Ambinder, Stefan Barta, et al. 2023.
736
-“Genetic Subgroups Inform on Pathobiology in Adult and Pediatric Burkitt
737
-Lymphoma.” *Blood* 141 8: 904–16.
738
-<https://doi.org/10.1182/blood.2022016534>.
739
-
740
-</div>
741
-
742
-<div id="ref-tiacciPervasiveMutationsJAKSTAT2018b" class="csl-entry">
743
-
744
-Tiacci, Enrico, Erik Ladewig, Gianluca Schiavoni, Alex Penson,
745
-Elisabetta Fortini, Valentina Pettirossi, Yuchun Wang, et al. 2018.
746
-“Pervasive Mutations of JAK-STAT Pathway Genes in Classical Hodgkin
747
-Lymphoma.” *Blood* 131 22: 2454–65.
748
-<https://doi.org/10.1182/blood-2017-11-814913>.
749
-
750
-</div>
751
-
752
-<div id="ref-wenigerMutationsTumorSuppressor2006a" class="csl-entry">
753
-
754
-Weniger, M. A., I. Melzner, C. K. Menz, S. Wegener, A. J. Bucur, K.
755
-Dorsch, T. Mattfeldt, T. F. E. Barth, and P. Möller. 2006. “Mutations of
756
-the Tumor Suppressor Gene SOCS-1 in Classical Hodgkin Lymphoma Are
757
-Frequent and Associated with Nuclear Phospho-STAT5 Accumulation.”
758
-*Oncogene* 25 18: 2679–84. <https://doi.org/10.1038/sj.onc.1209151>.
759
-
760
-</div>
761
-
762
-<div id="ref-wienandGenomicAnalysesFlowsorted2019b" class="csl-entry">
763
-
764
-Wienand, Kirsty, Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, David
765
-Wu, Jaegil Kim, Atanas Kamburov, et al. 2019. “Genomic Analyses of
766
-Flow-Sorted Hodgkin Reed-Sternberg Cells Reveal Complementary Mechanisms
767
-of Immune Evasion.” *Blood Advances* 3 23: 4065–80.
768
-<https://doi.org/10.1182/bloodadvances.2019001012>.
769
-
770
-</div>
771
-
772
-<div id="ref-wildaInactivationARFMDM2p53Pathway2004" class="csl-entry">
773
-
774
-Wilda, M., J. Bruch, L. Harder, D. Rawer, A. Reiter, A. Borkhardt, and
775
-W. Woessmann. 2004. “Inactivation of the <span
776
-class="nocase">ARF-MDM-2-p53</span> Pathway in Sporadic Burkitt’s
777
-Lymphoma in Children.” *Leukemia* 18 3: 584–88.
778
-<https://doi.org/10.1038/sj.leu.2403254>.
779
-
780
-</div>
781
-
782
-<div id="ref-wuGeneticHeterogeneityPrimary2016" class="csl-entry">
783
-
784
-Wu, Chenglin, Noel Fcc de Miranda, Longyun Chen, Agata M. Wasik, Larry
785
-Mansouri, Wojciech Jurczak, Krystyna Galazka, et al. 2016. “Genetic
786
-Heterogeneity in Primary and Relapsed Mantle Cell Lymphomas: Impact of
787
-Recurrent CARD11 Mutations.” *Oncotarget* 7 25: 38180–90.
788
-<https://doi.org/10.18632/oncotarget.9500>.
789
-
790
-</div>
791
-
792
-<div id="ref-yanBCRTLRSignaling2012a" class="csl-entry">
793
-
794
-Yan, Qingguo, Yuanxue Huang, A. James Watkins, Sylvia Kocialkowski,
795
-Naiyan Zeng, Rifat A. Hamoudi, Peter G. Isaacson, Laurence de Leval,
796
-Andrew Wotherspoon, and Ming-Qing Du. 2012. “BCR and TLR Signaling
797
-Pathways Are Recurrently Targeted by Genetic Changes in Splenic Marginal
798
-Zone Lymphomas.” *Haematologica* 97 4: 595–98.
799
-<https://doi.org/10.3324/haematol.2011.054080>.
800
-
801
-</div>
802
-
803
-<div id="ref-yildizActivatingSTAT6Mutations2015c" class="csl-entry">
804
-
805
-Yildiz, Mehmet, Hongxiu Li, Denzil Bernard, Nisar A. Amin, Peter
806
-Ouillette, Siân Jones, Kamlai Saiya-Cork, et al. 2015. “Activating STAT6
807
-Mutations in Follicular Lymphoma.” *Blood* 125 4: 668–79.
808
-<https://doi.org/10.1182/blood-2014-06-582650>.
809
-
810
-</div>
811
-
812
-<div id="ref-zhangGeneticHeterogeneityDiffuse2013" class="csl-entry">
813
-
814
-Zhang, Jenny, Vladimir Grubor, Cassandra L Love, Anjishnu Banerjee,
815
-Kristy L Richards, Piotr A Mieczkowski, Cherie Dunphy, et al. 2013.
816
-“Genetic Heterogeneity of Diffuse Large <span
817
-class="nocase">B-cell</span> Lymphoma.” January.
818
-
819
-</div>
820
-
821
-</div>
145
+# References